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Opinion statement
Instead of relying on crude peanut extract, component-resolved diagnostics (CRD) uses
sensitization to allergenic proteins within peanut. In this review, we describe the recent
advances and future perspectives of the use of CRD in the management of peanut-allergic
patients. There is strong evidence that sensitization to Ara h 2 is the best predictor for
clinically relevant peanut allergy in children and adults. Isolated sensitization to other
peanut components is only rarely present in patients with systemic reactions to peanut. It
is, however, important to remark that cut-off points of sIgE to Ara h 2 that predict
tolerance or allergy vary between different study populations, different age groups and
geographical regions, and validation studies performed in different settings are necessary
to implement cut-offs in daily practice. Future studies should focus on the role of CRD in
risk-assessment early in life, predicting long-term tolerance and monitoring treatment
responses following immunotherapy.
* The Author(s) 2016. This article is published with open access at Springerlink.com
Introduction
Peanut is one of the most common allergens capable of
eliciting severe allergic reactions [1]. Moreover, peanut
allergy can already appear during early childhood and
often persists throughout life [2••]. Depending on the
geographical region studied and definition of allergy
used, peanut allergy is estimated to affect 0.2–3 % of
the population [3, 4]. Peanut allergy is suspected when
immediate allergic symptoms occur after peanut inges-
tion together with positive sensitization. Sensitization to
peanut can be detected by a raised level of specific IgE
(sIgE) or positive skin prick test (SPT). Sensitization is
not always accompanied with clinical reactivity. The
gold standard to diagnose peanut allergy is a double-
blind placebo-controlled food challenge (DBPCFC) [5].
However, the DBPCFC is a burdensome, expensive and
potentially dangerous procedure and therefore alterna-
tive ways to predict peanut allergy are strongly required
[6]. In addition, previous work indicated that (double-
blind) food challenges can be false-negative and are
subject to observer variability, especially when objective
symptoms are absent [7, 8].
In recent years, the role of sIgE to peanut com-
ponents in the diagnostic work-up of patients with
suspected peanut allergy has been extensively stud-
ied. Instead of relying on crude peanut extract,
component-resolved diagnostics (CRD) uses sensiti-
zation to purified or recombinant allergenic pro-
teins within peanut. CRD has proven to strongly
increase the diagnostic accuracy to test for peanut
allergy. Moreover, it is able to identify cross-
reactivity and has the potential to classify patients
at higher risk for systemic reactions [9]. Moreover,
reactivity to individual peanut allergens might be
able to predict resolution of peanut allergy and be
a target for immunotherapy [10•, 11].
In this review we describe the recent advances
and future perspectives of the use of CRD in the
management of peanut-allergic patients.
Peanut extract and components
Peanut (Arachis hypogaea) belongs to the botanical family Fabaceae which is
also known as Leguminosae and commonly known as the bean or pea family.
The protein content of peanut lies between 24–29% and ismostlymade of seed
or storage proteins [12].
Currently, 17 allergens (components) of peanut (Ara h 1–17) have been
identified in the official allergen nomenclature database [13]. Only the first nine
of those allergens have been studied in relation to peanut allergy in humans and
will, therefore, be part of this review. These allergens belong to the cupin (Ara h
1, 3), conglutin or prolamin (Ara h 2, 6, 7), profilin (Ara h 5), Bet v 1
homologous proteins or pathogenesis-related proteins of class 10 (PR-10) (Ara
h 8) or lipid transfer protein (Ara h 9) family. The allergens can also be divided
in more functional and clinically relevant categories: storage proteins, pollen-
associated proteins and plant pan allergens. The characteristics of peanut aller-
gens are shown in Table 1.
Storage proteins
Seed storage proteins Ara h 1, 2, 3, 6 and 7 have a high degree of thermal and
digestive stability [17]. As a result, they are themajor peanut allergens. Ara h 1 is
a 7S globulin and is recognized in 26-92 % of peanut-allergic patients [18–22,
23••, 24, 25•]. Between 20 and 80 % of peanut-allergic patients are sensitized
to the 11S globulin Ara h 3 [18–22, 23••, 24, 25•]. Ara h 3 and Ara h 4 are
isoforms of each other and considered to be the same allergen [26]. Ara h 2, 6
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and 7 belong to the 2S albumin protein family and have a high amount of
amino acid sequence identity [27]. Ara h 2 and Ara h 6 are considered as the
most potent allergens and are recognized by the majority (60–100 %) of
peanut-allergic patients in Western Europe and the USA [19, 20, 22, 24, 28].
However, only up to 60 % of the Mediterranean peanut-allergic patients show
raised levels of sIgE to Ara h 2 [23••, 29].
Bet v 1 homologous protein
Ara h 8 is an allergen of the PR-10 family and has low stability to roasting and
digestion. PR-10 allergens are common pan allergens in pollens and also
present in vegetables and fruits. Due to cross-reactivity with the birch pollen
allergen Bet v 1, sensitization to Ara h 8 is common especially in North-West
Europe [30, 31••]. Furthermore, Ara h 8 is also cross-reactive with Glym 4 from
soy and potentially with white lupine [32, 33].
Lipid transfer proteins
Ara h 9 has been identified as an important lipid transfer protein (LTP) allergen
in peanut, especially in the Mediterranean area [31••, 34]. LTPs are very stable
and LTP-sensitized patients can experience systemic allergic reactions in addi-
tion to oral allergy. A strong association between sensitization to the LTPs in
peach (Pru p 3) and peanut in Spain has been described [35]. Besides Pru p 3, it
has also been suggested that LTP from plane tree (Pla a 3) or mugwort (Art v 3)
can act as primary sensitizers [36, 37].
How to use CRD: in the diagnosis of peanut allergy
There is strong evidence that sIgE to Ara h 2 is the best predictor for peanut
allergy in children and adults [38••]. Depending on the population studied and
definitions used, sensitivity ranges from 60–100 % and specificity from 60 to
96 % when using a cut-off of 0.35 kU/L [18–22, 24, 39–41]. The best combi-
nation of positive and negative likelihood ratio was also found when using sIgE
to Ara h 2. Although it has been suggested that the prevalence and relative
importance of sIgE to Ara h 2 is lower in Mediterranean countries, sIgE to Ara h
2 also emerged as the best predictor in studies from Southern France and Spain
[20•, 26].
In daily practice, sIgE to Ara h 2 and peanut extract are both suitable
to exclude peanut allergy [38••]. However, sIgE to Ara h 2 is more
specific and sensitive to diagnose peanut allergy. An 80–95 % NPV was
reached when using sIgE to Ara h 2 levels of G0.35 kU/L and a 100 %
NPV when a cut-off level of G0.1 kU/L was used [28, 42]. Moreover a
95–100 % PPV was reached when using sIgE to Ara h 2 levels 95 kU/L
to diagnose peanut allergy [28, 40]. By using optimal cut-off points for
sIgE to Ara h 2 (i.e. with the highest NPV and PPV) peanut allergy
could be diagnosed without a food challenge in the majority of subjects
suspected of peanut allergy. However, it should be noticed that current
available cut-off points were estimated in a selected group of referred
patients and, therefore, cannot be generalized to other centres without
validation studies. Furthermore, data in adults and young children
(G4 years) are currently lacking.
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It should also be kept in mind that in some cases of peanut allergy,
other peanut components are relevant [43•, 44•]. Allergic patients
without sIgE to Ara h 2 but with Ara h 1 or Ara h 3 sensitization have
been reported occasionally [31••, 42]. The sensitivity of sIgE to Ara h 1
and Ara h 3 is generally low but varies extensively between studies (26–
92 % and 21–84 %), mainly depending on the geographical region
[38••]. Two studies in children and adults describe that the diagnostic
accuracy of sIgE to Ara h 6 is comparable to sIgE to Ara h 2 [23••, 39].
This can be explained by the homology and cross-reactivity between
these two 2S albumins [27]. In adults, it was advocated that Ara h 6
could have additional value to Ara h 2 in individual cases with a
strongly suspected peanut allergy in which sIgE to Ara h 2 was absent or
very low [25•, 42]. The diagnostic value of sIgE to Ara h 8 is low with a
sensitivity ranging from 16 to 42 % and specificity from 31 to 100 %.
Isolated Ara h 8 sensitization is often related to Bet v 1 sensitization
and associated with tolerance or mild local symptoms [30, 45]. In a
Mediterranean region, Ara h 9 can detect LTP-related peanut sensitiza-
tion; however, the added value of sIgE to Ara h 9 is questionable as cases of
peanut allergy with isolated Ara h 9 sensitization are rare [25•, 42].
In summary, sIgE to Ara h 2 is the best diagnostic test to diagnose or exclude
a possible peanut allergy. In case of a suspected peanut allergy and absence of
sIgE to Ara h 2, additional peanut components can be determined to detect
relevant other sensitization. In older children and adults with a suspected Bet v
1 related peanut allergy sIgE to Ara h 8 can be useful. In adults and childrenwith
highly suspected primary peanut allergy sensitization to other storage proteins
(Ara h 1, h 3 and h 6) can be relevant.
How to use CRD: in the prediction of severe peanut allergy
We concluded that sIgE to Ara h 2 could reduce the number of food challenges.
However, next to diagnostic purposes, food challenges are used to provide
useful information regarding the severity of peanut allergy and subjective and
objective eliciting doses.
The severity of allergic symptoms during challenge correlated with higher
levels of Ara h 2 in several studies [19, 25•, 46]. Furthermore, higher levels of
sIgE to Ara h 2 were associated with lower thresholds during food challenges in
children and adults [19, 47]. However, contrasting results and large individual
variation in the relation between Ara h 2 and severity of peanut allergy exist [19,
48]. There are several explanations for the absence of a strong and consistent
association between sIgE to Ara h 2 and severity of peanut allergy. Firstly,
challenges can underestimate severity of peanut allergy because they are usually
stopped when objective and not necessarily severe symptoms occur. Secondly,
in contrast to daily life, patients are in a relative stable situation during chal-
lenge (absence of co-factors like active allergic disease, infections or exercise)
[48, 49]. In addition, it was suggested that the correlation between sIgE to Ara h
2 and thresholds only applies to higher dose therefore to selected patient
populations only [19].
sIgE to the storage components Ara h 1, Ara h 3 and Ara h 6 have also been
related to severity but the best correlation was found for Ara h 2 [19, 25•]. As is
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mentioned before, isolated sIgE to Ara h 8 is often related to mild symptoms. It
has been reported that allergic reactions can occur in rare cases if a large amount
of peanut is eaten over a short period of time [44•]. Furthermore, Ara h 8 is able
to activate basophils inmonosensitized children, and a recent report shows that
natural Ara h 8 from roasted peanuts has a reasonable degree of proteolytic and
thermal stability [50, 51].
In summary, severe peanut allergy is unlikely without IgE to any of the seed
storage proteins Ara h 1, 2, 3 or 6. Although Ara h 2 is correlated to severity, we
cannot use the level of sIgE to Ara h 2 or other components to classify individual
patients at higher risk for severe allergic symptoms during challenge or in daily
life.
Other aspects of CRD
Despite the promising results of CRD in diagnosing and excluding peanut
allergy, there are several important aspects of CRD that have to be considered
when using and interpreting CRD in daily practice.
Singleplex versus multiplex
Besides determination of sIgE to individual components (singleplex) with the
ImmunoCAP method (Thermo Fisher, Uppsala, Sweden), it is also possible to
simultaneously determine sIgE to a large number of components by the use of
biochip technology (multiplex) like the ImmunoCAP ISAC (Thermo Fisher,
Uppsala, Sweden). The multiplex assay requires less blood and allergen and
facilitates the identification of (cross-reactive) sensitization patterns [52•].
Several studies compared the singleplex and multiplex method for peanut
allergens and showed high correlation between the two methods [53, 54].
However, it has to be considered that the multiplex method has potentially
lower analytical sensitivity [23••]. Furthermore, the ISAC requires manual
procedures and results are semi-quantitative (expressed in standardized units).
In general, multiplex CRD should, therefore, be used to investigate complex
cases like patients with multiple food allergies, idiopathic anaphylaxis or severe
allergic symptoms without sensitization to Ara h 2 and not as a primary
diagnostic test [55].
Availability of allergens
One of the limitations of the use of whole peanut extract in sIgE testing is that
the conventional extracts vary in composition and are deficient in some IgE
components [56]. However, relevant sensitization can still be missed when
using CRD because some peanut allergens related to (severe) allergy might not
have been identified. Moreover, some allergens that were characterized are not
yet commercially available or investigated in clinical studies (Ara h 5, Ara h 7) or
are only available in multiplex tests (Ara h 6), see also Table 1.
Variability in CRD pattern within and between patient groups
The diagnostic value of different components is affected by several patient
related factors. Age dependency of sensitization patterns was described. Several
studies demonstrate that older peanut-allergic patients were more often
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sensitized to Ara h 8 in contrast to children with early onset allergy that
recognize predominately Ara h 2 and to a lesser extent Ara h 1 and h 3 [31••, 57,
58]. Additionally, geographical variation in sensitization patterns presumably
due to differences in exposure to other plant allergens, dietary habits and
genetics [31••, 34]. Although sIgE to Ara h 2 seems accurate in diagnosing and
excluding peanut allergy in different parts of the world, cut-off points may vary
between countries. As mentioned before, additional components may play a
role in certain regions (like Ara h 9 in Mediterranean countries).
Validation studies
Prospective validation studies that include follow-up to detect false-negative
(e.g. allergic reactions in patients with undetectable sIgE to Ara h 2) or false
positive tests (negative challenges despite high levels of sIgE to Ara h 2) are
needed. Those studies are necessary to further confirm the added value of CRD
in daily practice and determine cost-effectiveness. Furthermore validation of
CRD in other settings (e.g. secondary care), young children and in different
regions of the world is necessary as the diagnostic accuracy and therefore cut-off
points of a test vary with the pre-test probability of disease.
Future perspectives of CRD
Risk-assessment early in life
The Learning About Peanut Allergy study showed that early oral introduction of
peanuts was able to successfully prevent allergy in high-risk infants [59]. Peanut
avoidance was associated with an increase in peanut wheal size and a higher
proportion of patients with high levels of sIgE to peanut. At this moment it is
unknown whether CRD in those very young children can be used to predict an
increased risk for (severe) peanut allergy and is useful in deciding which
children should introduce peanut early in life.
Predicting development of tolerance
Results from the population-based Health Nuts Study showed that in 22 % of
children with positive challenge in their first year of life outgrew their peanut
allergy at year four [2••]. Like in several other studies, an increased SPT and sIgE
response to peanut indicated persistent peanut allergy [60–62]. However, sIgE
to Ara h 2 at year one was not predictive for persistence of peanut allergy [2••].
Further studies are required to investigate whether the course of sIgE to Ara h 2
over time is related to resolution or persistence of peanut allergy.
Selection of patients for food challenges
The DBPCFC is the current gold standard to diagnose peanut allergy but
burdensome and expensive, partly because the test takes 2 or even 3 days (open
challenge). Based on validated cut-off points, sIgE to Ara h 2 can be used to
reduce the amount of food challenges or food challenge days. For example,
patients with sIgE to Ara h 2 above the cut-off point with a 100%PPV (i.e. 5 kU/
L) are considered to have peanut allergy in our centre. If objectification of
symptoms andmore information about the threshold and severity is necessary,
it could be speculated that in these patients the DBPCFC can be replaced by a
single-day verum challenge. Furthermore, in patients with a low suspicion of
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peanut allergy and absence of sIgE to Ara h 2, clinical reintroduction (i.e. an
open challenge with peanut butter) or even introduction at home can be
advocated. It should be investigated whether certain diagnostic strategies are
safe and associated with reduced health care costs and improved quality of life.
Usefulness of components in other diagnostic tools
Peanut components Ara h 1, Ara h 2, Ara h 3 and Ara h 8 have been investigated
in the basophil activation test (BAT) [50, 63, 64]. These results indicated that the
basophil response to peanut components was related to clinical relevant peanut
allergy and might have a higher PPV compared to sIgE to peanut components.
However, more data is necessary and several practical limitations (absence of a
standardized protocol, fresh whole blood samples are necessary, high costs)
prevent current implementation of the BAT in daily practice [65]. Furthermore,
in our recent study, we could not confirm the added value of the BAT in
predicting severe peanut allergy (manuscript submitted). Skin prick tests (SPT)
with peanut components were performed in the past and indicated the relative
importance of Ara h 2 and Ara h 6 compared to Ara h 1 and Ara h 3 [66].
Furthermore, a correlation between the number of components detected in the
skin prick test correlated with severity of peanut allergy was found on group
level [67]. Although results are promising, the future of the SPT as a diagnostic
test is questionable as the SPT is prone to observer (measurement and inter-
pretation of wheal size), device and extract variability. Furthermore, tight reg-
ulations have made the production of extracts problematic [68].
Relation to treatment response
Patients responsive to oral and sublingual immunotherapy had lower
sIgE levels to peanut components Ara h 1, Ara h 2 and h 3 at baseline
and at the end of studies while IgG4 binding increased at the same
epitopes [10•, 69, 70]. In those studies, cut-off points of baseline Ara h
Table 2. The role of CRD in the management of peanut-allergic patients
CRD as diagnostic
tool
• Sensitization to Ara h 2 is the best predictor for clinically relevant peanut allergy in children and
adults.
• Cut-off points of sIgE to Ara h 2 that predict tolerance or allergy vary with age, geographical region and
study populations and validation studies performed in different settings would be necessary to
implement cut-offs in daily practice.
• In the absence of sensitization to Ara h 2, other peanut components should be considered in select
patient groups:
° Isolated Ara h 1, h 3 and h 6 sensitization
° Isolated Ara h 8 sensitization is not rare and often related to Bet v 1 sensitization and mostly
associated with tolerance or mild local symptoms in older children and adults
° Especially in Mediterranean patients relevant isolated sensitization to Ara h 9 occurs in rare cases
• Singleplex assays are preferred in patients presenting with suspected peanut allergy.
CRD in relation to
severity
• Levels of sIgE to Ara h 2 or other components are correlated to severity but cannot be used to classify
individual patients at higher risk for severe allergic symptoms.
Future perspectives • At this moment, the role of CRD in risk-assessment early in life, predicting long-term tolerance or
treatment responses is unclear.
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2 with 65–70% sensitivity and 90% specificity have been published that could
predict (long-term) responsiveness to immunotherapy. However, the added
value of sIgE to Ara h 2 was debatable as sIgE to peanut extract had comparable
discriminative capacity. At this moment further studies are required to deter-
mine whether CRD is able to select patients for immunotherapy and predict the
long term outcome of treatment strategies.
Conclusion
The highlights of this review are presented in Table 2. In summary, we can
conclude that CRD plays an essential role in the diagnostic evaluation of a
patient with suspected peanut allergy. sIgE to Ara h 2 is the best predictor for
peanut allergy and is preferred as first diagnostic step. Clinicians should be
aware that cases of (severe) peanut allergy, sIgE to other peanut components
(Ara h 1, Ara h 3, Ara h 6, Ara h 8 and Ara h 9)may be relevant. At this moment,
CRD cannot be used to predict the risk of a severe allergic reaction in individual
patients. The role of CRD in predicting long-term tolerance early in life and
treatment response deserves further investigation.
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